Bernstein downgrades Alnylam Pharmaceuticals to Market Perform from Outperform, lowers price target to $199
Bernstein downgraded Alnylam Pharmaceuticals to Market Perform, lowering its price target to $199 from $376. The new target suggests a 14.4% upside from the Oct 29 close of $174. Recent analyst price targets for the company range from $220 to $320.
How this was made
The 30-second read
Why it matters
The 47% price‑target reduction suggests a significant shift in earnings expectations.
Market read
The downgrade is a fresh analyst action that could move ALNY shares lower in the short term.
What to watch
Potential upcoming clinical data could offset the downgrade impact.
Background
Bernstein's downgrade follows recent analyst coverage with targets ranging $220‑$320.
Ticker impact
Bernstein downgraded Alnylam Pharmaceuticals to Market Perform and cut its price target to $199.
likely downside as investors price in the lower target
Analyst downgrades historically lead to short-term price declines, especially with a 47% target cut.
Market effects
Biotech sector may see modest pressure as analysts reassess valuations.
US biotech stocks could experience slight pullback.
Limited to investors tracking US biotech equities.
Counterpoint
Some investors may view the target cut as an overreaction and look for buying opportunities.
Key entities
- companyAlnylam Pharmaceuticals
US‑listed RNAi therapeutics company.
- analyst_firmBernstein
Equity research firm providing the downgrade.
